Economics and Precision Medicine.
Budget impact analysis
Cost-effectiveness analysis
Decision-analytic model
Discrete choice experiment
Economic evaluation
Microcosting
Pharmacoeconomics
Stated preferences
Value of implementation
Value of information
Journal
Handbook of experimental pharmacology
ISSN: 0171-2004
Titre abrégé: Handb Exp Pharmacol
Pays: Germany
ID NLM: 7902231
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
4
9
2023
pubmed:
30
6
2022
entrez:
29
6
2022
Statut:
ppublish
Résumé
Introducing precision medicine strategies into routine practice will require robust economic evidence. Decision-makers need to understand the value of a precision medicine strategy compared with alternative ways to treat patients. This chapter describes health economic analysis techniques that are needed to generate this evidence. The value of any precision medicine strategy can be demonstrated early to inform evidence generation and improve the likelihood of translation into routine practice. Advances in health economic analysis techniques are also explained and their relevance to precision medicine is highlighted. Ensuring that constraints on delivery are resolved to increase uptake and implementation will improve the value of a new precision medicine strategy. Empirical methods to quantify stakeholders' preferences can be effective to inform the design of a precision medicine intervention or service delivery model. A range of techniques to generate relevant economic evidence are now available to support the development and translation of precision medicine into routine practice. This economic evidence is essential to inform resource allocation decisions and will enable patients to benefit from cost-effective precision medicine strategies in the future.
Identifiants
pubmed: 35768553
doi: 10.1007/164_2022_591
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-281Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Abel L, Shinkins B, Smith A, Sutton A, Sagoo G, Uchegbu I, Allen A, Graziadio S, Moloney E, Yang Y, Hall P (2019) Early economic evaluation of diagnostic technologies: experiences of the NIHR diagnostic evidence co-operatives. Med Decis Making 39:857–866
pubmed: 31556806
Annemans L, Redekop K, Payne K (2013) Current methodological issues in the economic assessment of personalized medicine. Value Health 16:S20–S26
pubmed: 24034308
Basu A, Meltzer D (2005) Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ 24:751–773
pubmed: 15960995
Bowling A (2004) Measuring health: a review of quality of life measurement scales, 3rd edn. Open University Press, Maidenhead
Brazier J, Ratcliffe J, Salomon J, Tsuchiya A (2017) Measuring and valuing health benefits for economic evaluation, 2nd edn. Oxford University Press, Oxford
Brennan A, Chick S, Davies R (2006) A taxonomy of model structures for economic evaluation of health technologies. Health Econ 15:1295–1310
pubmed: 16941543
Briggs A, O'Brien B (2001) The death of cost-minimization analysis? Health Econ 10:179–184
pubmed: 11252048
Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
Brouwer W, Koopmanschap M (2000) On the economic foundations of CEA. Ladies and gentlemen, take your positions! J Health Econ 19:439–459
pubmed: 11010234
Brouwer W, Culyer A, van Exel N, Rutten F (2008) Welfarism vs. extra-welfarism. J Health Econ 27:325–338
pubmed: 18179835
Cancer Research UK (2015) Molecular diagnostic provision in England: for targeted cancer medicines (solid tumour) in the NHS. Concentra, London
Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, Brazier J, O'Hagan T (2005) Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 14:339–347
pubmed: 15736142
Coast J (2004) Is economic evaluation in touch with society's health values? BMJ 329:1233–1236
pubmed: 15550430
pmcid: 529373
Coast J, Smith R, Lorgelly P (2008a) Should the capability approach be applied in health economics? Health Econ 17:667–670
pubmed: 18457341
Coast J, Smith R, Lorgelly P (2008b) Welfarism, extra-welfarism and capability: the spread of ideas in health economics. Soc Sci Med 67:1190–1198
pubmed: 18657346
Culyer A (1989) The normative economics of health care financing and provision. Oxford Rev Econ Policy 5:34–58
Dalal G, Wright S, Vass C, Davison N, Stichele G, Smith C, Griffiths C, Payne K, PSORT Consortium (2021) Patient preferences for stratified medicine in psoriasis: a discrete choice experiment. Br J Dermatol 185:978–987
pubmed: 33991338
Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108
pubmed: 9366889
Dolan P (2008) Developing methods that really do value the 'Q' in the QALY. Health Econ Policy Law 3:69–77
pubmed: 18634633
Drummond M, Sculpher M, Claxton K, Stoddart G, Torrance G (2015) Methods for the economic evaluation of health care programmes, 4th edn. Oxford University Press, Oxford
Eden M, Payne K, Combs R, Hall G, McAllister M, Black G (2013) Valuing the benefits of genetic testing for retinitis pigmentosa: a pilot application of the contingent valuation method. Br J Ophthalmol 97:1051–1056
pubmed: 23743435
Eichler H, Kong S, Gerth W, Mavros P, Jönsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7:518–528
pubmed: 15367247
Elliott R, Payne K (2005) Essentials of economic evaluation in healthcare. The Pharmaceutical Press, London
EuroQol Group (1990) EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 16:199–208
EuroQol Group (2020) EQ-5D-5L | Valuation | New UK EQ-5D-5L Valuation Study | BLOG. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/new-uk-eq-5d-5l-valuation-study_blog/ . Accessed 10 Feb 2022
EuroQol Group (2021) EQ-5D-5L | Valuation: Standard value sets. https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/ . Accessed 10 Feb 2022
Ezennia I, Nduka S, Ekwunife O (2017) Cost benefit analysis of malaria rapid diagnostic test: the perspective of Nigerian community pharmacists. Malar J 16:1–10
Faulkner E, Holtorf A, Walton S, Liu C, Lin H, Biltaj E, Brixner D, Barr C, Oberg J, Shandhu G, Siebert U, Snyder S, Tiwana S, Watkins J, IJzerman M, Payne K (2020) Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group. Value Health 23:529–539
pubmed: 32389217
Fenwick E, Claxton K, Sculpher M (2008) The value of implementation and the value of information: combined and uneven development. Med Decis Making 28:21–32
pubmed: 18263559
Fenwick E, Steuten L, Knies S, Ghabri S, Basu A, Murray J, Koffijberg H, Strong M, Schmidler G, Rothery C (2020) Value of information analysis for research decisions – an introduction: report 1 of the ISPOR value of information analysis emerging good practices task force. Value Health 23:139–150
pubmed: 32113617
Frick K (2009) Microcosting quantity data collection methods. Med Care 47:S76–S81
pubmed: 19536026
pmcid: 2714580
Garrison L, Mestre-Ferrandiz J, Zamora B (2016) The value of knowing and knowing the value: improving the health technology assessment of complementary diagnostics. Health Economics and EPEMED, London
Gavan S, Thompson A, Payne K (2018) The economic case for precision medicine. Expert Rev Precis Med Drug Dev 3:1–9
pubmed: 29682615
pmcid: 5890303
Glick H, Doshi J, Sonnad S, Polsky D (2015) Economic evaluation in clinical trials, 2nd edn. Oxford University Press, Oxford
Goranitis I, Best S, Christodoulou J, Stark Z, Boughtwood T (2020) The personal utility and uptake of genomic sequencing in pediatric and adult conditions: eliciting societal preferences with three discrete choice experiments. Genet Med 22:1311–1319
pubmed: 32371919
pmcid: 7394876
Gray A, Clarke P, Wolstenholme J, McInstosh E (2011) Applied methods of cost-effectiveness analysis in health care. Oxford University Press, Oxford
Grutters J, Govers T, Nijboer J, Tummers M, van der Wilt G, Rovers M (2019) Problems and promises of health technologies: the role of early health economic modeling. Int J Health Policy Manag 8:575–582
pubmed: 31657184
pmcid: 6819627
Han L, Zhang X, Fu W, Sun C, Zhao X, Zhou L, Liu G (2020) A systematic review of the budget impact analyses for antitumor drugs of lung cancer. Cost Eff Resour Alloc 18:1–10
Hatz M, Schremser K, Rogowski W (2014) Is individualized medicine more cost-effective? A systematic review. Pharmacoeconomics 32:443–455
pubmed: 24574059
Herbst R, Fukuoka M, Baselga J (2004) Gefitinib – a novel targeted approach to treating cancer. Nat Rev Cancer 4:956–965
pubmed: 15573117
Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs A, Carswell C, Caulley L, Chaiyakunapruk N, Greenberg D, Loder E, Mauskopf J, Mullins C, Petrou S, Pwu R, Staniszewska S (2022) Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health 25:10–31
pubmed: 35031088
IJzerman M, Koffijberg H, Fenwick E, Krahn M (2017) Emerging use of early health technology assessment in medical product development: a scoping review of the literature. Pharmacoeconomics 35:727–740
pubmed: 28432642
pmcid: 5488152
ISPOR (2022a) Good practices reports & more. https://www.ispor.org/heor-resources/good-practices . Accessed 10 Feb 2022
ISPOR (2022b) Pharmacoeconomic guidelines around the world. https://tools.ispor.org/peguidelines/ . Accessed 10 Feb 2022
Jani M, Gavan S, Chinoy H, Dixon W, Harrison B, Moran A, Barton A, Payne K (2016) A microcosting study of immunogenicity and tumour necrosis factor alpha inhibitor drug level tests for therapeutic drug monitoring in clinical practice. Rheumatology 55:2131–2137
pubmed: 27576368
pmcid: 5144665
Kaltenthaler E, Tappenden P, Paisley S, Squires H (2011) NICE DSU technical support document 13: identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models. Decision Support Unit, Sheffield
Kirchheiner J, Schmidt H, Tzvetkov M, Keulen J, Lötsch J, Roots I, Brockmöller J (2006) Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J 7:257–265
pubmed: 16819548
Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland C, Ford J, Elkin E, Phillips K (2011) Strategies to identify the lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med 155:69–79
pubmed: 21768580
pmcid: 3793257
Maynard A, Kanavos P (2000) Health economics: an evolving paradigm. Health Econ 9:183–190
pubmed: 10790697
McIntosh E, Clarke P, Frew E, Louviere J (2010) Applied methods of cost-benefit analysis in health care. Oxford University Press, Oxford
Mihaylova B, Briggs A, O'Hagan A, Thompson S (2011) Review of statistical methods for analysing healthcare resources and costs. Health Econ 20:897–916
pubmed: 20799344
Morris S, Devlin N, Parkin D, Spencer A (2007) Economic analysis in health care, 2nd edn. Wiley, Chichester
National Institute for Health and Care Excellence (2013) Guide to the methods of technology appraisal 2013: process and methods [PMG9]. National Institute for Health and Care Excellence, Manchester
Neyt M, Hulstaert F, Gyselaers W (2014) Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open 4:1–10
Ng Y (1983) Welfare economics: introduction and development of basic concepts, 2nd edn. The Macmillan Press Ltd, London
Paulden M (2020) Calculating and interpreting ICERs and net benefit. Pharmacoeconomics 38:785–807
pubmed: 32390067
Payne K (2009) Fish and chips all round? Regulation of DNA-based genetic diagnostics. Health Econ 18:1233–1236
pubmed: 19821463
Payne K, Newman W, Gurwitz D, Ibarreta D, Phillips K (2009) TPMT testing in azathioprine: a ‘cost-effective use of healthcare resources?’. Pers Med 6:103–113
Payne K, Fargher E, Roberts S, Tricker T, Elliott R, Ratcliffe J, Newman W (2011) Valuing pharmacogenetic testing services: a comparison of patients' and health care professionals' preferences. Value Health 14:121–134
pubmed: 21211494
Payne K, Gavan S, Wright S, Thompson A (2018) Cost-effectiveness analyses of genetic and genomic diagnostic tests. Nat Rev Genet 19:235–246
pubmed: 29353875
Pearson E (2016) Personalized medicine in diabetes: the role of 'omics' and biomarkers. Diabet Med 33:712–717
pubmed: 26802434
pmcid: 4879510
Philips Z, Bojke L, Sculpher M, Claxton K, Golder S (2006) Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 24:355–371
pubmed: 16605282
Phillips K, Sakowski J, Liang S, Ponce N (2013) Economic perspectives on personalized health care and prevention forum health econ. Policy 16:S23–S52
Phillips K, Sakowski J, Trosman J, Douglas M, Liang S, Neumann P (2014) The economic value of personalized medicine tests: what we know and what we need to know. Genet Med 16:251–257
pubmed: 24232413
Pipitprapat W, Pattanaprateep O, Iemwimangsa N, Sensorn I, Panthan B, Jiaranai P, Chantratita W, Sorapipatcharoen K, Poomthavorn P, Mahachoklertwattana P, Sura T, Tunteeratum A, Srichan K, Sriphrapradang C (2021) Cost-minimization analysis of sequential genetic testing versus targeted next-generation sequencing gene panels in patients with pheochromocytoma and paraganglioma. Ann Med 51:1243–1255
Regier D, Veenstra D, Basu A, Carlson J (2020) Demand for precision medicine: a discrete-choice experiment and external validation study. Pharmacoeconomics 38:57–68
pubmed: 31489595
Roberts M, Russell L, Paltiel A, Chambers M, McEwan P, Krahn M, ISPOR-SMDM Modeling Good Research Practices Task Force (2012) Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task Force-2. Value Health 15:804–811
pubmed: 22999129
pmcid: 4207095
Rogowski W, Payne K, Schnell-Inderst P, Manca M, Rochau R, Jahn B, Alagoz O, Leidl R, Siebert U (2015) Concepts of ‘personalization’ in personalized medicine: implications for economic evaluation. Pharmacoeconomics 33:49–59
pubmed: 25249200
pmcid: 4422179
Ryan M, Gerard K, Amaya-Amaya M (2008) Using discrete choice experiments to value health and health care. Springer, Dordrecht
Sculpher M, Drummond M, Buxton M (1997) The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy 2:26–30
pubmed: 10180650
Sculpher M, Claxton K, Drummond M, McCabe C (2006) Whither trial-based economic evaluation for health care decision making? Health Econ 15:677–687
pubmed: 16491461
Skivington K, Matthews L, Simpson S, Craig P, Baird J, Blazeby J, Boyd K, Craig N, French D, McIntosh E, Petticrew M, Rycroft-Malone J, White M, Moore L (2021) Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update. Health Technol Assess 25:1–132
pubmed: 34590577
pmcid: 7614019
Smith R (2003) Construction of the contingent valuation market in health care: a critical assessment. Health Econ 12:609–628
pubmed: 12898660
Smith R, Sach T (2009) Contingent valuation: (still) on the road to nowhere? Health Econ 18:863–866
pubmed: 19565468
Smith R, Sach T (2010) Contingent valuation: what needs to be done? Health Econ Policy Law 5
Sullivan S, Mauskopf J, Augustovski F, Caro J, Lee K, Minchin M, Orlewska E, Penna P, Barrios J, Shau W (2014) Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health 17:5–14
pubmed: 24438712
Thompson A, Newman W, Elliott R, Roberts S, Tricker K, Payne K (2014) The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health 17:22–33
pubmed: 24438714
Thorn J, Davies C, Brookes S, Noble S, Dritsaki M, Gray E, Hughes D, Mihaylova B, Petrou S, Ridyard C, Sach T, Wilson E, Wordsworth S, Hollingworth W (2021) Content of health economics analysis plans (HEAPs) for trial-based economic evaluations: expert Delphi consensus survey. Value Health 24:539–547
pubmed: 33840432
pmcid: 8024512
UKRI (2022) Area of investment and support: precision medicine. https://www.ukri.org/our-work/browse-our-areas-of-investment-and-support/precision-medicine/ . Accessed 10 Feb 2022
van Hout B, Janssen M, Feng Y, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard A (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15:708–715
pubmed: 22867780
Vass C, Barton A, Payne K (2022) Towards personalising the use of biologics in rheumatoid arthritis: a discrete choice experiment. Patient 15:109–119
pubmed: 34142326
Walker D, Wilson R, Sharma R, Bridges J, Niessen L, Bass E, Frick K (2012) Best practices for conducting economic evaluations in health care: a systematic review of quality assessment tools. Agency for Healthcare Research and Quality, Rockville
Wilson E (2015) A practical guide to value of information analysis. Pharmacoeconomics 33:105–121
pubmed: 25336432
Wright S, Daker-White G, Newman W, Payne K (2018) Understanding barriers to the introduction of precision medicines in non-small cell lung cancer: a qualitative interview protocol. Wellcome Open Res 3:1–12
Wright S, Newman W, Payne K (2019) Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review. Pharmacoeconomics 37:1011–1027
pubmed: 31087278
pmcid: 6597608
Wright S, Paulden M, Payne K (2020) Implementing interventions with varying marginal cost-effectiveness: an application in precision medicine. Med Decis Making 40:924–938
pubmed: 33081576
pmcid: 7583450
Wright S, Newman W, Payne K (2021) Quantifying the impact of capacity constraints in economic evaluations: an application in precision medicine. Med Decis Making
Zorginstituut Nederland (2016) Guideline for economic evaluations in healthcare. Zorginstituut Nederland, Diemen